Decreased Mdm2 Expression Inhibits Tumor Development and Extends Survival Independent of Arf and Dependent on p53

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Eischen, Christine M ^a   Boyd, Kelli ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; PROTEIN MDM2; PROTEIN P53;

ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; HAPLOINSUFFICIENCY; HETEROZYGOSITY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIMARY TUMOR; PROTEIN DEFECT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROZYGOTE; MICE; MICE, INBRED C57BL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84866999012     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046148     Document Type: Article

References (23)

1. Bond GL, Hu W, Levine AJ, (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC, (1991) p53 mutations in human cancers. Science 253: 49-53.
3. Sherr CJ, (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737.
4. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL, (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
5. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
6. Levine AJ, Oren M, (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
7. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
9. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ, (1999) Tumor spectrum in ARF-deficient mice. Cancer Res 59: 2217-2222.
10. Wang P, Greiner TC, Lushnikova T, Eischen CM, (2006) Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 25: 3708-3718.
11. Moore L, Venkatachalam S, Vogel H, Watt JC, Wu CL, et al. (2003) Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene 22: 7831-7837.
12. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, et al. (2000) p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 14: 2358-2365.
13. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A, (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 95: 15608-15612.
14. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, et al. (1999) Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 188: 322-328.
15. Eischen CM, Alt JR, Wang P, (2004) Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23: 8931-8940.
16. Ozenne P, Eymin B, Brambilla E, Gazzeri S, (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127: 2239-2247.
17. Whibley C, Pharoah PD, Hollstein M, (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
18. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res 66: 5104-5110.
19. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, et al. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16-21.
20. Alt JR, Greiner TC, Cleveland JL, Eischen CM, (2003) Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22: 1442-1450.
21. O'Leary KA, Mendrysa SM, Vaccaro A, Perry ME, (2004) Mdm2 Regulates p53 Independently of p19(ARF) in Homeostatic Tissues. Mol Cell Biol 24: 186-191.
22. Bouska A, Eischen CM, (2009) Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 34: 279-286.
23. Jones SN, Sands AT, Hancock AR, Vogel H, Donehower LA, et al. (1996) The tumorigenic potential and cell growth characteristics of p53- deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A 93: 14106-14111.